1. RNA-based therapies: A cog in the wheel of lung cancer defense
   Parvez Khan et al, 2021, Molecular Cancer CrossRef
2. Identification of a novel DNA repair inhibitor using an in silico driven approach shows effective combinatorial activity with genotoxic agents against multidrug‐resistant Escherichia coli
   Lorenzo Bernacchia et al, 2024, Protein Science CrossRef
3. Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro
   Sophie F. Ellermann et al, 2022, Frontiers in Pharmacology CrossRef
4. The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
   Yun Beom Sang et al, 2022, Frontiers in Oncology CrossRef
5. Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
   Amita Patnaik et al, 2022, Targeted Oncology CrossRef
6. Bioluminescent RAPPID Sensors for the Single-Step Detection of Soluble Axl and Multiplex Analysis of Cell Surface Cancer Biomarkers
   Eva A. van Aalen et al, 2022, Analytical Chemistry CrossRef
7. Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers
   Avinash Khadela et al, 2024, Clinical Medicine Insights: Oncology CrossRef
8. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis
   Tung-Wei Hsu et al, 2023, Aging CrossRef
9. Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma
   Yeliz Yılmaz et al, 2021, Liver Cancer in the Middle East CrossRef
10. AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers
    Xiaobai Sun et al, 2023, Molecular and Clinical Oncology CrossRef